AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

AtriCure, a leader in surgical treatments for atrial fibrillation, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. A conference call will follow at 4:30 p.m. ET the same day, accessible via phone or live audio webcast. AtriCure offers innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® products, which are widely used for managing Afib. With over 33 million people affected by Afib globally, AtriCure is committed to improving patient outcomes.

Positive

• Innovative technologies for Afib treatment, including the Isolator® Synergy™ Ablation System, the first FDA-approved device for persistent Afib.
• AtriClip® products are the most widely sold left atrial appendage management devices globally.

Negative

• None.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, February 15, 2022 to discuss its fourth quarter and full year 2021 financial results. The call may be accessed through an operator by dialing (844) 884-9951 for domestic callers and (661) 378-9661 for international callers, using conference ID number 4299852. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the webcast will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005013/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Lynn Lewis

Gilmartin Group

Investor Relations

(415) 937-5402

lynn@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When will AtriCure release its fourth quarter 2021 financial results?

AtriCure will release its fourth quarter and full year 2021 financial results on February 15, 2022.

What time is AtriCure's conference call to discuss the financial results?

The conference call will be held at 4:30 p.m. Eastern Time on February 15, 2022.

How can I access AtriCure's conference call?

The conference call can be accessed by dialing (844) 884-9951 for domestic calls or (661) 378-9661 for international calls, using conference ID number 4299852.

What is AtriCure's focus in the medical field?

AtriCure focuses on innovative technologies for the treatment of atrial fibrillation and related conditions.